AMMILATE Trademark

Trademark Overview

On Thursday, May 16, 2019, a trademark application was filed for AMMILATE with the United States Patent and Trademark Office. The USPTO has given the AMMILATE trademark a serial number of 79261300. The federal status of this trademark filing is REGISTERED as of Tuesday, January 28, 2020. This trademark is owned by Glaxo Group Limited. The AMMILATE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
ammilate

General Information

Serial Number79261300
Word MarkAMMILATE
Filing DateThursday, May 16, 2019
Status700 - REGISTERED
Status DateTuesday, January 28, 2020
Registration Number5969885
Registration DateTuesday, January 28, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 12, 2019

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 25, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type11 - Company
AddressGB
Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type11 - Company
AddressMiddlesex TW8 9GS
GB
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type11 - Company
AddressMiddlesex TW8 9GS
GB

Trademark Events

Event DateEvent Description
Wednesday, July 19, 2023CHANGE OF NAME/ADDRESS REC'D FROM IB
Monday, August 1, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, August 1, 2022TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Monday, August 1, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, August 1, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, May 29, 2020FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, May 13, 2020FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, May 13, 2020FINAL DISPOSITION PROCESSED
Tuesday, April 28, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, January 28, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, November 12, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 12, 2019PUBLISHED FOR OPPOSITION
Saturday, November 9, 2019NOTIFICATION PROCESSED BY IB
Wednesday, October 23, 2019NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, October 23, 2019NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, October 23, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, October 10, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, October 8, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, October 8, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, October 7, 2019ASSIGNED TO LIE
Wednesday, October 2, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, September 13, 2019REFUSAL PROCESSED BY IB
Friday, August 23, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, August 22, 2019REFUSAL PROCESSED BY MPU
Friday, August 2, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, August 1, 2019NON-FINAL ACTION WRITTEN
Monday, July 29, 2019NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Saturday, July 6, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, July 5, 2019NON-FINAL ACTION WRITTEN
Thursday, July 4, 2019ASSIGNED TO EXAMINER
Saturday, June 29, 2019APPLICATION FILING RECEIPT MAILED
Tuesday, June 25, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 20, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

ammilate pharmaceutical treatment disorders preparations substances diseases ophthalmic respiratory hepatological oncological